CannabisNewsBreaks – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) to Secure $11.25 Million in Bought Deal Public Offering

Cardiol Therapeutics (TSX: CRDL) (OTCQX: CRTPF), a leader in the production of pharmaceutical cannabidiol (“CBD”) and the development of innovative cannabidiol products for heart diseases, recently announced its entry into an agreement with Canaccord Genuity Corp. (the “Lead Underwriter”). Under the arrangement, the Lead Underwriter agreed, on behalf of a syndicate of underwriters, to purchase, on a bought deal basis per the filing of a short form prospectus, an aggregate of 4,500,000 units, each at a price of $2.50, for aggregate gross proceeds of $11,250,000 to the Company. Cardiol intends to use the proceeds to support commercialization of its pharmaceutical cannabidiol products, its ongoing research and clinical development programs focused on heart failure, additional product development, as well as for general corporate purposes.

To view the full press release, visit http://cnw.fm/9otIJ

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is focused on producing pharmaceutical cannabidiol (“CBD”) products and developing innovative therapies for heart diseases, including acute myocarditis and other causes of heart failure. The Company’s lead product, CardiolRx(TM), is formulated to be the most consistent cannabidiol formulation on the market. CardiolRx is pharmaceutically produced, manufactured under cGMP, and is THC free (<5 ppm). The Company also plans to commercialize CardiolRx in the billion-dollar market for medicinal cannabinoids in Canada and is pursuing distribution opportunities in Europe and Latin America.

In heart failure, Cardiol is planning an international clinical study of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary nanotechnology to uniquely deliver pharmaceutical cannabidiol and other anti-inflammatory drugs directly to sites of inflammation in the heart associated with heart failure. Heart failure is the leading cause of death and hospitalization in North America with associated annual healthcare costs in the U.S. alone exceeding $30 billion. For further information about Cardiol Therapeutics, please visit CardiolRX.com.

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1)  access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

Next-level cannabis investor forum MjMicro debuts in NYC on June 25

MjMicro Conference (www.mjmicro.com), the next-level investor forum for publicly traded cannabis companies, debuts in New York City on June 25 at the Westin Grand Central Hotel. This one-day conference provides an exceptional opportunity for cannabis-related public entities to connect with private capital investors and also features presentations from noted industry experts.

The MjMicro Conference is an invitational networking forum exclusively created to enable best-in-class and emerging public companies in the cannabis industry to meet with high-net-worth investors, venture funds and family offices, helping drive private investment capital into public entities, promote trading liquidity, and increase media and analyst coverage.

“Our goal is to provide both the most exciting and diverse range of public company investment opportunities, ranging from micro to mid-cap companies that have proof of concept, revenue streams, audited financials and public market liquidity,” noted George Jage, president of MjLink.com and producer of MjMicro. “This event creates direct C-suite access for investors to provide insight into their vision, strategy and performance.”

Confirmed presenting companies include 1933 Industries (CSE: TGIF) (OTCQX: TGIFF), CannAmerica Brands (CSE: CANA) (OTCQB: CNNXF), Cannex Capital Holdings (CSE: CNNX) (OTC: CNXXF), Cardiol Therapeutics (TSE: CRDL) (OTC: CRTPF), Dixie Brands (CSE: DIXI.U), (OTC: DXBRF), (Frankfurt: 0QV), Emerald Health Therapeutics, FSD Pharma (CSE: HUGE) (OTCQB: FSDDF), Helix TCS Inc. (OTCQB: HLIX), High Tide Inc. (CSE:HITI) (OTCQB:HITIF), House of Jane, Province Brands of Canada, MJ Freeway, Tauriga Sciences (OTCQB: TAUG), United Cannabis Corp. (OTCQB: CNAB), and Vireo Health (OTC: VREOF).

“FSD Pharma, a spotlight presenter, is endemic of the exciting opportunities in the market. They are a Canadian licensed producer developing cutting-edge technology and conducting research related to the treatment of chronic pain, fibromyalgia and other medical conditions that are typically treated with pharmacological applications,” noted Todd Markey, director of investor relations at MjMicro.

“There are over 400 cannabis-related public companies in the market today, and we project that anywhere between 100 and 200 others will get listed in the next 24 months,” stated Jage. “There has been a race for cannabis companies to access the public capital markets, but the industry lacks the access to institutional capital that you would expect in such a fast-growth industry. This event provides the solution on both sides of the table.”

MjMicro is scheduled to be held four times a year with events in New York, Beverly Hills, West Palm Beach and Seattle.  MjMicro is produced by MjLink.com Inc., which is a wholly owned subsidiary of Social Life Networks (OTC: WDLF).

To learn more about MjMicro Conference or to request an invitation to attend, sponsor or present, please visit https://www.mjmicro.com.

About MjLink.com Inc.

Social Life Network (OTC: WDLF), a cloud-based social media and social network technology company based in Denver, Colorado, announced on Sept. 25, 2018, that the Company had spun its cannabis technology division out of the parent company and incorporated MjLink.com Inc., a Delaware Corporation, as its wholly owned subsidiary. MjLink operates as a multinational cannabis technology and media organization with two separate social networks: WeedLife.com, a consumer-to-consumer network; and MjLink.com, a business-to-business social network. On April 4, 2019, the president of MjLink, George Jage, announced the launch of a new division of the Company that is focused on providing the industry with best-in-class financial, B2B and B2C cannabis-centric events that complement the Company’s global social networks.

For more information about Social Life Network and to download the MjLink Investor Deck, visit https://social-life-network.com

Disclaimer

This news release may include forward-looking statements within the meaning of section 27A of the United States Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company’s analysis of opportunities in the acquisition and development of various project interests and certain other matters. No information in this press release should be construed as any indication whatsoever of the Company’s or MjLink’s future financial results, revenues or stock price. There are no assurances that the Company will successfully take MjLink.com, Inc public. These statements are made under the “Safe Harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein. The relationship between Social Life Network and the other companies mentioned currently does not extend beyond inviting them to send representatives to speak at the MjMicro Conference.

Contact:

Investor Relations:
IR@Social-Life-Network.com
855-933-3277

Corporate Communications:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

This article contains Third-Party Content submitted by third parties, including articles submitted through the CNW Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of CNW or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and CNW does not endorse, guarantee or make representations concerning the accuracy and completeness of all third-party content. You acknowledge that by CNW providing you with this internet portal that makes accessible to you the ability to view third-party content through the CNW site, CNW does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. CNW expressly disclaims liability relating to such third-party content. CNW and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, CNW reserves the right to remove third-party content at any time in its sole discretion.